RetinalGenix Technologies (RTGN) Other financing activities (2024)

RetinalGenix Technologies (RTGN) reported Other financing activities of $60000.0 for Q2 2024, down 60.0% sequentially from $150000.0 in Q1 2024.

RetinalGenix Technologies (RTGN) Other financing activities (2024) Analysis & Trends

RetinalGenix Technologies (RTGN) has 1 years of Other financing activities data on file, last reported at $60000.0 in Q2 2024.

For the quarter ending Q2 2024, Other financing activities changed N/A year-over-year to $60000.0; the trailing twelve-month figure through Dec 2024 stood at $210000.0 (changed N/A YoY), and the FY2024 full-year result was $210000.0, changed N/A from the prior year.
Other financing activities declined to $60000.0 in Q2 2024, from $150000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $150000.0 in Q1 2024 to a low of $60000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	184.32 Bn	177.02 Bn	6.27 Bn
2	Stryker	128.89 Bn	126.01 Bn	3.81 Bn
3	Medtronic	108.88 Bn	99.66 Bn	6.41 Bn
4	Boston Scientific	68.65 Bn	67.20 Bn	3.61 Bn
5	Edwards Lifesciences	47.43 Bn	43.76 Bn	1.29 Bn
6	GE HealthCare Technologies	28.48 Bn	26.19 Bn	1.98 Bn
7	Dexcom	28.45 Bn	27.33 Bn	750.30 Mn
8	Smith & Nephew	26.98 Bn	26.40 Bn	-
9	Koninklijke Philips	25.54 Bn	22.42 Bn	2.07 Bn
10	RetinalGenix Technologies	75.02 Mn	75.02 Mn	-

Download Data